286 related articles for article (PubMed ID: 34285339)
1. Functional genomics for breast cancer drug target discovery.
Yoshimaru T; Nakamura Y; Katagiri T
J Hum Genet; 2021 Sep; 66(9):927-935. PubMed ID: 34285339
[TBL] [Abstract][Full Text] [Related]
2. Breast Cancer: Current Molecular Therapeutic Targets and New Players.
Nagini S
Anticancer Agents Med Chem; 2017; 17(2):152-163. PubMed ID: 27137076
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapy of metastatic breast cancer.
Sánchez-Muñoz A; Pérez-Ruiz E; Jiménez B; Ribelles N; Márquez A; García-Ríos I; Alba Conejo E
Clin Transl Oncol; 2009 Oct; 11(10):643-50. PubMed ID: 19828406
[TBL] [Abstract][Full Text] [Related]
4. Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family.
Lin ML; Park JH; Nishidate T; Nakamura Y; Katagiri T
Breast Cancer Res; 2007; 9(1):R17. PubMed ID: 17280616
[TBL] [Abstract][Full Text] [Related]
5. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
6. New concepts in breast cancer genomics and genetics.
Goncalves R; Warner WA; Luo J; Ellis MJ
Breast Cancer Res; 2014; 16(5):460. PubMed ID: 25606588
[TBL] [Abstract][Full Text] [Related]
7. Development of small molecular compounds targeting cancer stem cells.
Park JH; Chung S; Matsuo Y; Nakamura Y
Medchemcomm; 2017 Jan; 8(1):73-80. PubMed ID: 30108692
[TBL] [Abstract][Full Text] [Related]
8. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.
Conte P; Guarneri V; Bengala C
Clin Breast Cancer; 2007 Dec; 7(11):841-9. PubMed ID: 18269773
[TBL] [Abstract][Full Text] [Related]
9. Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer.
Awada G; Gombos A; Aftimos P; Awada A
Expert Opin Emerg Drugs; 2016; 21(1):91-101. PubMed ID: 26817602
[TBL] [Abstract][Full Text] [Related]
10. The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy.
Austreid E; Lonning PE; Eikesdal HP
Expert Opin Pharmacother; 2014 Apr; 15(5):681-700. PubMed ID: 24579888
[TBL] [Abstract][Full Text] [Related]
11. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
12. Overcoming endocrine resistance in hormone receptor-positive breast cancer.
AlFakeeh A; Brezden-Masley C
Curr Oncol; 2018 Jun; 25(Suppl 1):S18-S27. PubMed ID: 29910644
[TBL] [Abstract][Full Text] [Related]
13. Targeted Therapies for Brain Metastases from Breast Cancer.
Venur VA; Leone JP
Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27649142
[TBL] [Abstract][Full Text] [Related]
14. Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.
Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Corominas-Faja B; Urruticoechea A; Martin-Castillo B; Menendez JA
Oncotarget; 2012 Dec; 3(12):1600-14. PubMed ID: 23307622
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers of drugs targeting HER-family signalling in cancer.
Montemurro F; Scaltriti M
J Pathol; 2014 Jan; 232(2):219-29. PubMed ID: 24105684
[TBL] [Abstract][Full Text] [Related]
16. Precision Medicine and Targeted Therapies in Breast Cancer.
Greenwalt I; Zaza N; Das S; Li BD
Surg Oncol Clin N Am; 2020 Jan; 29(1):51-62. PubMed ID: 31757313
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.
Glackin CA
Enzymes; 2018; 44():83-101. PubMed ID: 30360816
[TBL] [Abstract][Full Text] [Related]
18. Chemical genomics reveals inhibition of breast cancer lung metastasis by Ponatinib via c-Jun.
Shao W; Li S; Li L; Lin K; Liu X; Wang H; Wang H; Wang D
Protein Cell; 2019 Mar; 10(3):161-177. PubMed ID: 29667003
[TBL] [Abstract][Full Text] [Related]
19. Drug repositioning based on gene expression data for human HER2-positive breast cancer.
Khanjani F; Jafari L; Azadiyan S; Roozbehi S; Moradian C; Zahiri J; Hasannia S; Sajedi RH
Arch Biochem Biophys; 2021 Nov; 712():109043. PubMed ID: 34597657
[TBL] [Abstract][Full Text] [Related]
20. Proteomics as a Guide for Personalized Adjuvant Chemotherapy in Patients with Early Breast Cancer.
Lumachi F; Chiara GB; Foltran L; Basso SM
Cancer Genomics Proteomics; 2015; 12(6):385-90. PubMed ID: 26543084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
